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ABSTRACT: Airway inflammation and remodelling play an important role in the
pathophysiology of asthma. Remodelling may affect childhood lung function, and this
process may be reversed by anti-inflammatory treatment. The current study assessed
longitudinally whether asthma affects growth of airway function relative to airspaces,
and if so whether this is redressed by inhaled corticosteroids (ICS).
Every 4 months for up to 3 yrs, lung function was assessed in 54 asthmatic children
(initial age 7–16 yrs), who inhaled 0.2 mg salbutamol t.i.d. and 0.2 mg budesonide t.i.d.
(b2-agonist (BA)zICS), or placebo (PL) t.i.d. (BAzPL) in a randomised, double-blind
design. Measurements were carried out before and after maximal bronchodilation.
Airway growth was assessed from the change of forced expiratory volume in one second
and of maximal expiratory flows (at 60% and 40% of total lung capacity (TLC)
remaining in the lung) relative to TLC, as measures of more central, intermediate and
more peripheral airways. Growth patterns were compared with the longitudinal findings
in 376 healthy children.
Airway patency after maximal bronchodilation in patients on BAzPL remained
reduced compared to healthy subjects, whereas in patients on BAzICS a marked
improvement was observed to subnormal. No differences between patients and controls
could be demonstrated for growth patterns of central and intermediate airway function.
Compliance with BAzICS was 75% of the prescribed dose, resulting in significant,
sustained improvement of symptoms and postbronchodilator calibre of central and
intermediate airways to subnormal within 2 months, but postbronchodilator small
airway patency remained reduced, though improved compared to patients on BAzPL.
Anti-inflammatory treatment of asthmatic children is associated with normal
functional development of central and intermediate airways. The persistently reduced
postbronchodilator patency of peripheral airways may reflect remodelling, or
insufficient anti-inflammatory treatment.
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Distinct histopathological changes occur in the central
airways of children with mild [1] to severe [2, 3] asthma, but
the direct relationship between such structural alterations and
functional deterioration is unclear. Although between 30–70%
of asthmatic children improve or "grow out of asthma" in late
adolescence or early adulthood [4–7], young asthmatic patients
who have become asymptomatic may still have residual histo-
logical abnormalities [8, 9], airways obstruction [6, 10, 11],
and elevated lung volumes [6, 12–14]. Furthermore, the
decline of lung function with ageing in adult asthmatics appears
to occur at a greater rate than in nonasthmatic subjects [5, 7,
15] and long-standing asthma may be difficult to distinguish
from chronic bronchitis and chronic obstructive pulmonary
disease (COPD) [16, 17]. These findings, and the concept of
asthmatic airway remodelling [1–3, 9, 18–20] suggest that
asthma is associated with progressive functional changes that
start in childhood, continue into adulthood, and may end in
COPD with a substantial irreversible component. Indeed,
some studies suggest that early intervention may favour long-
term outcome of lung function [21–23], although this was
not based on lung function data obtained after maximal
bronchodilation.
Airways obstruction throughout childhood asthma may be
due to factors such as diminished lung growth [24, 25],
enhanced bronchomotor tone and/or airway wall thickening
and remodelling due to airway inflammation. A longitudinal
study with maximal post-bronchodilator data would be
required to look into diminished airway growth, taking into
account any effects of anti-inflammatory drugs on lung
growth. Several prospective longitudinal studies that assessed
the effect of childhood asthma on the development of lung
function [5, 6, 11, 14] describe reduced expiratory flows
compared to normal subjects after correction for height and/
or age [5, 6, 11, 14], that could not always be detected by
measuring forced expiratory volume in one second (FEV1) [6,
11, 14]. One should be cautious to infer from these studies
that lung growth is diminished in asthma. First, conclusions
were based on prebronchodilator data so that enhanced
bronchomotor tone and/or inflammation were not ruled
out. Secondly, using reference equations rather than healthy
controls may introduce artefacts: the relationship between
height and lung function during puberty is complex [26, 27],For editorial comments see page 795.
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and a delayed pubertal growth spurt in asthmatics [28] may
introduce additional problems. Thirdly, total lung capacity
(TLC), and not forced vital capacity (FVC), should be used as
a measure of lung size because residual volume (RV)/TLC
depends on sex and increases with age during puberty [29–31],
and because airway closure in asthmatic children may be
more pronounced than in controls [29, 30].
The aim of the present study was to investigate the growth
of airways and airspaces in children with moderate asthma
who were treated at random with inhaled placebo or
corticosteroids in a fixed dose, irrespective of symptoms.
Prospective lung function measurements were obtained prior
to and after maximal bronchodilation during a median period
of 22 months. This study was part of a large multicentre
intervention study carried out between 1988–1992, which
demonstrated that anti-inflammatory treatment in childhood
asthma results in an improvement in symptoms, exacerbation
rates, hospital admissions, and bronchial hyperresponsiveness
[32]. The current study used measures of airway function,
expressed as a per cent of TLC to correct for lung size, to
avoid spurious results due to differences between the sexes.
Sex-specific reference equations were not used because of the
artefacts that occur during the pubertal growth spurt [26, 27].
The present authors assumed that airflow limitation during a
forced expiration reflects wave speed flow in progressively
more distal airways during the expiration, and that FEV1,
maximum expiratory flow at 60% of TLC (MEF60%TLC),
and MEF40%TLC reflect airway patency when choke points
are located in more central (trachea and main bronchi)
airways, intermediate (2nd and 3rd generation) airways and in
more distal (4th–6th generations) airways, as was measured
intrabronchially in adults with severe asthma and in healthy
controls [33]. Airway function was corrected for lung size
(TLC) and compared with those obtained in a large
longitudinal study in nonsmoking Dutch children without
respiratory symptoms [26, 29].
Material and methods
Subjects
The study subjects consisted of asthmatic patients who
participated in a clinical trial [32], and were recruited between
1988 and 1992 from the outpatient clinics for respiratory
medicine of the Juliana Children9s Hospital, The Hague, and
the Rotterdam University Hospital/Sophia Children9s Hospi-
tal. Inclusion criteria were: 1) moderate to moderately severe
asthma [34], defined as a history of chronic or episodic
shortness of breath, wheeze and/or cough; 2) FEV1 55–90% of
predicted [35] and/or FEV1/FVC 50–75%; 3) a provocative
dose of histamine that caused a reduction in FEV1 by 20%
(PD20)v150 mg; 4) ages 7–16 yrs. The reference population
comprised 287 male and 89 female children who participated
in a longitudinal study and who had had no respiratory
symptoms prior to and during that study [26, 31]. Every 6
months for up to 7 yrs anthropometric and lung function data
were obtained. Informed consent was obtained from partici-
pants and their parents, and the local medical ethics commi-
ttees approved the study.
Design
Prior to the study, corticosteroid or cromones were tapered
off. During the 4 week run-in period medication consisted of
inhaled b2-agonist (BA) on demand. Next, baseline lung
function was assessed and patients were randomly allocated
to one of two treatment arms with stratification for sex, age,
hospital and prior use of inhaled corticosteroid (ICS) and/or
cromoglycate [32]. Double-blind inhalation medication con-
sisted of salbutamol 0.2 mg plus budesonide 0.2 mg t.i.d.
(BAzICS) or placebo (PL) t.i.d. (BAzPL) via a spacer
(Volumatic1). For the purpose of this study, all cannisters
were of the same design to fit into the same spacer. Additional
inhaled fenoterol was allowed up to 4 times daily. When more
than four courses of prednisolone were needed in 12 months,
patients were withdrawn from the study. Compliance with
therapy was estimated from canister weight loss.
Maximal bronchodilation and lung function
measurements
In patients, maximum expiratory flow volume (MEFV)
curves and measurements of total lung capacity (TLC) were
obtained once every 4 months for up to 3 yrs, before and
20 min after bronchodilation achieved with 2 sequential
inhalations of (800z200) mg salbutamol at 20 min intervals,
using a spacer (Volumatic 1) [36]. From a previous study in
78 asthmatic children (age range: 9–18 yrs) with a baseline
FEV1 ranging from 41 to 109% pred, it was concluded that
this dosage was sufficient to obtain maximal bronchodilation.
After 1,000 mg salbutamol, a plateau was reached in the dose/
response curve for all parameters from the MEFV curve, with
values that did not differ from those obtained after 1,200 mg
salbutamol, and this occurred irrespective of severity of
airways obstruction (personal communication: P.J.F.M.
Merkus, Sophia Children9s Hospital, Erasmus University
Medical Center, Rotterdam, The Netherlands). In healthy
controls composite MEFV-curves were constructed using the
same protocol as in patients [26]. RV and TLC were
determined by the nitrogen forced re-breathing technique
which has been validated in subjects with [37] and without [38]
airways obstruction.
Development of airway function in asthma
In healthy controls and in asthmatic patients,
MEF60%TLC and MEF40%TLC remaining in the lung
were calculated through interpolation of MEFV data super-
imposed on TLC. Development of pulmonary function with
age was assessed from FEV1%TLC, MEF60%TLC and
MEF40%TLC as measures of central, intermediate and
peripheral airway calibre, respectively. RV and FEV1 were
expressed as the per cent of TLC, and MEF60%TLC and
MEF40%TLC were expressed in TLC per second, to correct
for lung size.
Data analysis
Healthy subjects were included in the analyses if their
follow-up lasted at least 18 months. Patient data were
analysed if the follow-up was at least 1 yr while on the
same treatment. Subjects were excluded from the analyses
when no significant growth of TLC was observed due to too
few data points, or at the end of puberty (defined as variation
smaller than the single measurement reproducibility [37]).
Development of pulmonary function with age within indivi-
duals was studied from least squares regression. This was
done after verification that the distributions of the data and
the residuals were normal and homoscedastic, respectively.
Measurement errors of maximal flow and TLC were
estimated and employed to obtain maximum likelihood
estimates [39], yielding slopes and intercepts corrected for
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measurement errors. Differences between normal subjects,
and asthmatic patients according to sex, treatment and
bronchodilation were assessed using ANOVA of the mean
slopes of these regression lines.
Results
Sixty-five patients (45 males) participated in the study.
Baseline data are summarised in table 1. Pulmonary function
indices at the start and end of the study are summarised in
tables 2 and 3. Within a year of randomisation, six males
receiving BAzPL dropped out and could therefore not be
included in the analyses; one male withdrew from the study
for nonmedical reasons, five others demonstrated clinical
deterioration requiring rescue medication too often. Because
of a selective and significant dropout of patients inhaling
BAzPL an independent monitoring committee decided to
discontinue the BAzPL treatment after a median follow-up of
22 months [32]. Hence, median follow-up in the BAzICS
group was longer than in the BAzPL group. Clinical improve-
ment was observed in patients taking BAzICS, especially in
the first 2 months [32]. Of the remaining group of 59 patients
five were excluded (four on BAzPL) from the analyses
because no growth of TLC was observed (due to early
dropout or little growth at the end of puberty). The results
relate to 34 patients receiving BAzICS, and 20 patients taking
BAzPL who remained on the same treatment. The median
(range) follow-up of patients on BAzICS was longer: 2.9
(2.0–3.2) yrs, compared to those on BAzPL: 1.7 (0.8–2.2) yrs.
In healthy subjects RV/TLC in males and in females
differed significantly: at the age of 11 yrs mean¡SD RV/TLC
was 18.0¡5.3% and 20.0¡4.7%, respectively (pv0.001), with a
mean¡SD increase with age in both sexes of 0.7¡1.3% per yr.
In the two groups of patients RV/TLC decreased significantly
after bronchodilation (table 2); the values before and after
bronchodilation were similar for the sexes and larger than in
healthy subjects: at age 11 the mean (95% CI) difference in
postbronchodilator RV/TLC between patients and healthy
controls was 3.6 (1.7–5.4)% for males and 2.9 (0.6–5.2)% in
Table 1. – Baseline characteristics of both treatment groups
prior to randomisation
BAzPL BAzICS
Subjects n 30 35
F:M 23:7 22:13
Age yrs 10.9¡1.9 11.4¡2.1
Height cm 145.9¡12.0 150.0¡14.0
Weight kg 36.3¡11.4 36.7¡13.3
PD20 mg 25.7 (4.4–148) 18.2 (4.2–79.4)
Data are presented as mean¡SD or geometric mean (95% CI). BAzPL:
b2-agonistzplacebo; BAzICS: b2-agonistzinhaled corticosteroids; F:
female; M: male; PD20: provocative dose of histamine causing a 20%
fall in forced expiratory volume in one second.
Table 2. – Pulmonary function indices expressed in % predicted [35] or in % at the start of the study
BAzPL (n=20) BAzICS (n=34)
Baseline After maximal bronchodilation Baseline After maximal bronchodilation
PEF % pred 86.0¡17.8 101.8¡15.1# 87.0¡15.0 105.1¡15.9#
FEV1 % pred 73.5¡13.7 92.1¡11.3# 72.2¡11.4 93.1¡12.7#
FVC % pred 88.3¡12.5 95.6¡11.6# 86.2¡11.1 94.0¡12.4#
MMEF % pred 46.1¡14.3 74.7¡17.8# 45.3¡11.2 78.4¡16.1#
TLC % pred 99.3¡9.2 99.4¡10.8 96.9¡11.7 97.4¡12.9
MEF60%TLC/TLC % 41.6¡16.6 71.0¡20.9# 41.7¡19.9 72.3¡22.0#
MEF40%TLC/TLC % 14.8¡8.7 31.8¡11.8# 15.4¡15.3 33.1¡14.7#
FEV1/FVC % 69.8¡8.6 81.3¡7.0# 70.4¡5.5 83.4¡5.2#
FEV1/TLC % 52.3¡8.2 64.3¡6.3# 51.7¡8.5 64.4¡7.8#
RV/TLC % 28.4¡6.7 22.6¡4.9# 29.5¡8.0 22.3¡4.9#
BAzPL: b2-agonistzplacebo; BAzICS: b2-agonistzinhaled corticosteroids; PEF: peak expiratory flow; FEV1: forced expiratory volume in one
second; FVC: forced vital capacity; MMEF: maximal mid-expiratory flow; TLC: total lung capacity; MEF60%TLC, MEF60%TLC: maximum
expiratory flow at 60% or 40% of TLC, respectively; RV: residual volume; #: paired t-tests, pv0.0001.
Table 3. – Pulmonary function indices expressed in % predicted [35] or in % at the end of the study
BAzPL (n=20) BAzICS (n=34)
Baseline After maximal bronchodilation Baseline After maximal bronchodilation
PEF (% pred) 83.1 (15.0) 107.2 (20.1)# 105.3 (18.0) 114.7 (16.5)#
FEV1 (% pred) 72.1 (13.9) 94.8 (10.5)# 88.8 (14.9) 95.9 (21.4)#
FVC (% pred) 88.3 (12.1) 97.0 (10.8)# 93.3 (12.0) 96.1 (12.1)#
MMEF (% pred) 28.4 (10.6) 50.1 (12.9)# 48.0 (16.7) 62.6 (15.8)#
TLC (% pred) 94.7 (10.6) 94.7 (10.6) 95.6 (11.6) 95.1 (11.8)
MEF60%TLC/TLC % 34.7 (18.9) 69.2 (21.2)# 61.1 (25.5) 82.4 (24.3)#
MEF40%TLC/TLC % 11.4 (9.7) 29.2 (11.0)# 24.6 (14.9) 36.3 (15.4)#
FEV1/FVC % 68.5 (9.7) 81.5 (7.8)# 78.6 (7.2) 85.9 (5.1)#
FEV1/TLC % 48.2 (10.3) 63.0 (6.4)# 59.5 (9.0) 64.3 (12.7)#
RV/TLC % 33.5 (9.0) 27.0 (6.5)# 23.0 (7.6) 24.5 (5.9)
BAzPL: b2-agonistzplacebo; BAzICS: b2-agonistzinhaled corticosteroids; PEF: peak expiratory flow; FEV1: forced expiratory volume in one
second; FVC: forced vital capacity; MMEF: maximal mid-expiratory flow; TLC: total lung capacity; MEF60%TLC, MEF60%TLC: maximum
expiratory flow at 60% or 40% of TLC, respectively; RV: residual volume; #: paired t-tests, pv0.0001.
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females. The mean¡SD longitudinal increase of prebronchodilator
RV/TLC in patients (fig. 1) was different depending on
treatment (p=0.007), but treatment did not significantly affect
the evolution of postbronchodilator RV/TLC (p=0.52). The
mean¡SD longitudinal increase of postbronchodilator RV/
TLC in patients did not differ from that found in healthy
subjects (power 88%).
Development of ventilatory function with age
In healthy subjects, indices of airway calibre expressed as
FEV1%TLC, MEF60%TLC (TLC?s-1) and MEF40%TLC
(TLC?s-1) all declined significantly, and more so in females
than in males (table 4, fig. 2). In patients receiving BAzPL
postbronchodilator flows remained below the normal range
throughout the study, and the deficit was most pronounced
for MEF40%TLC. In patients inhaling BAzICS postbroncho-
dilator mean FEV1%TLC and MEF60%TLC fell generally in
the normal range (figs 2a–d), unlike MEF40%TLC (fig. 2e, f).
Postbronchodilator FEV1%TLC was similar for both treat-
ment groups, but MEF60%TLC and MEF40%TLC was
higher in patients on BAzICS treatment. No difference
between patients and healthy children could be demonstrated
with respect to the longitudinal development of postbronch-
odilator FEV1%TLC and MEF60%TLC. MEF40%TLC
expressed as TLC?s-1 declined faster in asthmatic males than
in healthy males (p=0.01, table 4). The changes of post-
bronchodilator measures of airway function were unrelated to
treatment except for MEF40%TLC which declined faster in
patients taking BAzPL than in those taking BAzICS
(table 5, ANOVA, p=0.01). The development of pre- and
postbronchodilator indices of airway calibre was significantly
different in patients taking BAzICS from those on BAzPL
(fig. 2). In the former, the difference between pre- and
postbronchodilator airway calibre decreased whereas in
patients on BAzPL it either increased or remained similar
during the study. Before randomisation, mean¡SEM FEV1
following maximal bronchodilation increased 17.7¡1.6 %
pred in BAzPL, and 20.4¡1.4 % pred in BAzICS. At the end
of the study, bronchodilator response in BAzPL had
increased to 22.7¡2.4 % pred (p=0.02) and bronchodilator
response in the BAzICS group had decreased to 11.6¡1.5 %
pred (pv0.001). Mean¡SD compliance with treatment in
patients on BAzPL was 430¡180 mg salbutamol and
470¡240 mg placebo, and in patients on BAzICS this was
450¡160 mg salbutamol and 453¡203 mg budesonide, respec-
tively, instead of 600 mg daily, and did not change during the
trial (p=0.15).
Discussion
Asthmatic inflammation of paediatric airways results in
histological changes [1–3, 8] that may account for persisting
functional abnormalities [5, 6, 11, 14, 16, 17] and progressive
decline in prebronchodilator airway calibre in adult asth-
matics [5, 7, 15]. This suggests that asthma is associated with
progressive functional deterioration starting in childhood [21,
40], evolving into chronic obstructive lung disease [5, 9, 19].
The mechanisms involved may be related to changes such as
diminished airway growth, changes of airway-parenchymal
interdependence, altered airways mechanics due to remodel-
ling, or phenomena such as enhanced bronchomotor tone and
inflammatory swelling of the bronchial mucosa. If inflamma-
tion and/or remodelling affect growth of airway function
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Fig. 1. – The effect of treatment on the longitudinal development of
residual volume (RV)/total lung capacity (TLC) a) before and b) after
bronchodilation. The solid lines refer to treatment with b2-agonist
(BA)zinhaled corticosteroids, the dashed lines refer to treatment with
BAzplacebo. Mean group trend and 95% CI are given.
Table 4. – Longitudinal development of postbronchodilator measures of airway calibre with age between healthy subjects and
patients according to sex
Subjects/patients Subjects n FEV1/TLC % per annum MEF60%TLC TLC?s-1 per annum MEF40%TLC TLC?s-1 per annum
Male children
Healthy 311 -0.2¡1.4 -1.1¡4.4 -0.2¡3.7
Asthmatic 36 -0.8¡1.9 -2.0¡5.7 -1.8¡3.3#
Female children
Healthy 113 -0.5¡1.1} -2.2¡4.2} -1.2¡3.6}
Asthmatic 18 -0.3¡2.0 -1.2¡6.6 -0.9¡5.1
Data are presented as means¡SD unless otherwise indicated; FEV1: forced expiratory volume in one second; TLC: total lung capacity;
MEF60%TLC, MEF40%TLC: maximum expiratory flow at 60% or 40% of TLC, respectively; }: ANOVA, pv0.02 healthy female children compared
to healthy male children; #: ANOVA, p=0.01 asthmatic male children compared to healthy male children.
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relative to lung parenchyma, but have an important reversible
component, airway function may normalise by treatment with
inhaled corticosteroids.
The current study found that in asthmatic children with no
anti-inflammatory treatment (BAzPL), airway patency after
maximal bronchodilation of central, intermediate and small
airways remained reduced, with no signs of catch-up growth
of airway function relative to lung volume. Randomised
treatment with inhaled corticosteroids during nearly 2 yrs
resulted in a significant and sustained improvement of pre-
and postbronchodilator expiratory flows, while growth of
central and intermediate airway function was not affected and
remained similar to that found in healthy subjects. At the
same time, symptom scores, bronchial hyperresponsiveness
and exacerbation rates improved dramatically [32]. It there-
fore appears that, during growth, at high levels of lung
inflation the combined effects of airway mechanics, airway
calibre and lung elastic recoil on expiratory flow were the
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Fig. 2. – a, b) Longitudinal development of forced expiratory volume in one second (FEV1)/total lung capacity (TLC) (%) in a) males and b)
females before and after maximal bronchodilation. c, d) Longitudinal development of maximum expiratory flow at 60% of TLC (MEF60%TLC
(TLC?s-1)) in c) asthmatic male children and d) asthmatic female children before and after maximal bronchodilation. e, f) Longitudinal
development of MEF40%TLC (TLC?s-1) in e) asthmatic male children and f) asthmatic female children before and after maximal
bronchodilation. Solid lines refer to the mean regression lines in patients receiving b2-agonist (BA)zinhaled corticosteroids (ICS), dashed lines
refer to the mean regression lines in patients receiving BAzplacebo (PL). Lines connecting closed symbols (lower lines) refer to prebronchodilator
data, lines connecting open symbols (upper lines) refer to postbronchodilator data. Dotted lines refer to the mean regression lines and 95% CI in
healthy subjects. Median follow-up of patients on BAzICS was longer than in those on BAzPL (see text).
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same in patients on BAzICS as in healthy subjects. However,
because of the relatively small group of asthmatic children,
this study probably lacks power to actually prove that level
and development of FEV1%TLC and MEF60%TLC are very
similar in patients and in controls. Furthermore, the differ-
ences in airway function between patients and controls is
likely to be underestimated because the controls did not
inhale bronchodilators. In addition, it cannot be excluded
that stiffening of asthmatic airways [33, 41, 42] might
compensate for irreversible airway narrowing due to remo-
delling. However these data suggest that normal functional
development of major and intermediate airways can be
achieved in children and adolescents with asthma on ICS
maintenance treatment, and that these children can enter
adulthood with a normal postbronchodilator FEV1, relative
to lung size.
The present study further demonstrates that development
of pre- and postbronchodilator lung function in asthmatic
children can differ markedly, depending on the type of
maintenance treatment. It also underlines that pre- and
postbronchodilator vital capacity are biased estimates of lung
size in asthma because RV/TLC in the patients was affected
by bronchomotor tone and type of maintenance treatment.
The decrease of prebronchodilator RV/TLC in patients on
BAzICS illustrates improvement of airway closure in that
group. These findings are consistent with the evolution of
other indices of airway calibre that differed according to
treatment. In patients on BAzPL bronchodilator responses
were unaffected or increased, whereas in patients on BAzICS
prebronchodilator airway calibre improved progressively, and
the difference with postbronchodilator airway calibre dimin-
ished. Thus, inhaled corticosteroids also acted as indirect
bronchodilators. It should be mentioned here that these
treatment effects may be underestimated because of a selective
dropout of patients on BAzPL with more severe respiratory
symptoms (leading to discontinuation of the BAzPL treat-
ment after a median follow-up of 22 months), with patients
remaining in the BAzPL treatment group with less severe
asthma than those in the BAzICS group [32].
However, in all patients, including those receiving BAzICS,
peripheral airway function as assessed from MEF40%TLC
after maximal bronchodilation was reduced and remained
below that in controls. Furthermore, airway closure as
assessed from postbronchodilator RV/TLC was increased
compared to healthy subjects, remaining abnormal in spite of
good adherence to anti-inflammatory treatment. These per-
sisting abnormalities are unlikely to be due to elevated
bronchomotor tone, as the protocol involved maximal
bronchodilation. Moreover, they may even be underestimated
because in healthy subjects lung function was assessed without
bronchodilation. They may reflect irreversible changes, or may
indicate that the dose and/or the deposition of budesonide was
insufficient to completely abolish peripheral airway wall
inflammation; possibly, MEF40%TLC and RV/TLC might
have improved further with higher topical dosages. The
effects of budesonide observed in the present study were due
to an average daily intake of 0.45 mg rather than the pres-
cribed 0.6 mg, and not associated with significant systemic
side-effects [43]. If bronchial hyperresponsiveness reflects
airway inflammation, there would indeed be some indication
that the patients on BAzICS still had active airway inflam-
mation: PD20 was still improving but had not normalised in
patients on BAzICS after a median follow-up of 22 months
[32]. In spite of this, the large majority of patients on BAzICS
became asymptomatic during the trial [32], implying that
these residual functional abnormalities may be statistically
significant, but not clinically relevant during childhood and
adolescence.
To the best of the authors9 knowledge, this is the first study
employing both maximal bronchodilation, and randomised
treatment with a fixed dose of inhaled corticosteroids, irres-
pective of respiratory symptoms. The only two longitudinal
studies that involved placebo-controlled anti-inflammatory
treatment and postbronchodilator lung function tests are the
Childhood Asthma Management Program (CAMP) study
[22] and the Inhaled Steroid Treatment as Regular Therapy in
Early Asthma (START) study [40]. The current study9s
conclusions are in contrast to those of the CAMP study,
in which administration of anti-inflammatory treatment to
children with mild asthma resulted in improved bronchial
hyperresponsiveness and symptom scores, reduced exacerba-
tion rates and use of rescue medication, and an improvement
of prebronchodilator FEV1 but not postbronchodilator
FEV1. In contrast to the present study, in the CAMP study,
bronchodilation was not maximal, children had less severe
asthma, the prescribed daily corticosteroid dose was 200 mg,
and it allowed corticosteroid treatment to taper off or stop
when symptoms improved, in line with international guide-
lines [34]. This may explain why no beneficial effect of inhaled
corticosteroids was observed in the CAMP study on post-
bronchodilator FEV1 compared to placebo treatment. In the
START study [40], children also had less severe asthma,
prescribed daily corticosteroid dose was 200 or 400 mg, and
the improvement of pre- and postbronchodilator FEV1
was significant, but not clinically relevant, (v3% of pred).
Furthermore, in the CAMP and START study, compliance
with treatment was not monitored, while in the current work
patients and their parents were aware that compliance was
monitored. Hence, the design of the studies, the asthma
severity and the differences in endpoints make these studies
difficult to compare.
In conclusion, in spite of the small sample size and the
methodological limitations of the present study, the conclu-
sion remains that residual functional abnormalities are
Table 5. – Annual change of postbronchodilator airway calibre in patients according to treatment and sex
Patients n FEV1/TLC % MEF60%TLC %TLC?s-1 MEF40%TLC %TLC?s-1
Male children
BAzPL 15 -0.9¡2.7 -2.3¡7.4 -1.7¡4.1
BAzICS 21 -0.7¡1.0 -1.8¡4.4 -1.7¡2.9
Female children
BAzPL 5 -0.9¡2.5 -0.2¡6.3 -1.9¡5.3
BAzICS 13 -0.1¡1.9 -1.6¡6.9 -0.6¡5.2
ANOVA
Treatment 0.40 0.81 0.01
Sex 0.64 0.55 0.30
Data are presented as means¡SD unless otherwise indicated; BAzPL: b2-agonistzplacebo; BAzICS: b2-agonistzinhaled corticosteroids; FEV1:
forced expiratory volume in one second; TLC: total lung capacity; MEF60%TLC, MEF40%TLC: maximum expiratory flow at 60% or 40% of TLC,
respectively.
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present in asymptomatic asthmatic children, even when a
daily dose of 600 mg budesonide is prescribed and broncho-
motor tone is completely abolished. This suggests that
anti-inflammatory treatment of asthmatic children based on
symptoms alone is not enough to result in normalisation of
postbronchodilator airway function. As in adults [44],
treatment with inhaled corticosteroids based on inflammatory
markers may be needed to further reduce airway inflamma-
tion, improve peripheral airway function and to achieve
optimal postbronchodilator lung function at the end of
adolescence. Whether such treatment of asthmatic children in
the absence of respiratory symptoms is realistic and can be
ethically justified is open to debate, and whether it is required
for optimal long-term prognosis remains to be shown.
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